R&D channel feed

In­novent says next-gen GLP-1 drug from Lil­ly beats top di­a­betes med in Phase 3 Chi­na study

Last year
China

Free­line un­veils ear­ly ef­fi­ca­cy sig­nal for Gauch­er gene ther­a­py: #AS­GCT24

Last year
Cell/Gene Tx

Cy­tomX shares plum­met as Am­gen-part­nered can­cer drug yields jum­bled Phase 1 da­ta

Last year

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Last year
AI

Te­va’s an­tipsy­chot­ic as­set pass­es Phase 3 test in schiz­o­phre­nia

Last year

As­traZeneca pulls Covid-19 vac­cine glob­al­ly as the phar­ma sees 'no fu­ture com­mer­cial de­mand'

Last year
Pharma
Coronavirus

Ex­clu­sive: Feng Zhang CRISPR start­up gath­ers patents, lock­ing up rights to fam­i­ly of edit­ing tech

Last year
Deals
Law

UPenn and Stan­ford analy­sis finds no sec­ondary can­cer cas­es di­rect­ly due to CAR-T

Last year
Cell/Gene Tx

ADC Ther­a­peu­tics re­veals topline Zyn­lon­ta da­ta, $105M stock of­fer­ing

Last year
Financing

J&J re­ports lat­est da­ta on Balver­sa-based ‘pret­zel’ ther­a­py for blad­der can­cer

Last year

Gly­coMimet­ic­s' AML drug flunks Phase 3 tri­al, quash­ing fil­ing plans as stock sinks

Last year

J&J show­cas­es more blad­der can­cer re­sults from 'pret­zel' drug-de­vice com­bo

Last year
Pharma

Ab­b­Vie puts $161M in­to new R&D site in Ger­many, will add 300 jobs

Last year
Pharma

CG On­col­o­gy touts in­ter­im Phase 3 blad­der can­cer da­ta, gears up to com­pete with Im­mu­ni­ty­Bio

Last year

AEON fails an­oth­er mi­graine tri­al, shares halve as com­pa­ny re­views op­tions

Last year

Am­gen touts new da­ta for obe­si­ty drug Mar­i­Tide, mov­ing rapid­ly in­to Phase 3 work

Last year

Block­buster can­cer drug Calquence hits pri­ma­ry end­point in tri­al for first-line man­tle cell lym­phoma

Last year
Pharma

FDA asks for more da­ta on Dupix­ent in COPD in move that could de­lay a de­ci­sion

Last year
Pharma
FDA+

As it cuts costs and pipeline, Bris­tol My­ers hands back a can­cer drug to Schrödinger

Last year

FDA de­ci­sion on Sarep­ta’s Duchenne gene ther­a­py could come ear­li­er than ex­pect­ed

Last year
Cell/Gene Tx
FDA+

Lil­ly scraps tri­als of Verzenio, Jar­diance and a gene ther­a­py from Pre­vail

Last year
Pharma

No­var­tis hands Pep­tiDream $180M up­front to ex­tend ra­dio­phar­ma dis­cov­ery pact

Last year
Deals

Mer­ck touts up­dat­ed 21-va­lent pneu­mo­coc­cal da­ta weeks ahead of FDA de­ci­sion: Cor­rect­ed

Last year

Prime Med­i­cine re­ceives FDA clear­ance to run first prime edit­ing clin­i­cal tri­al

Last year
Cell/Gene Tx
FDA+
First page Previous page 46474849505152 Next page Last page
A service from the Financial Times